Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Vectibix (panitumumab) - Important Safety Information from Amgen Europe B.V. as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
16/08/2013
Problem Or Issue:
Important Safety Information communication from Amgen Europe B.V. on the importance of establishing wild-type RAS (exons 2, 3 and 4 of KRAS and NRAS) status before treatment with Vectibix (panitumumab).
Important Safety Information - Vectibix (panitumumab)
« Back
Date Printed: 07/05/2024